Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Northwestern University
With
HepQuant, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects over the age of 18 able to provide consent
Subjects undergoing initial TIPS procedure for the primary indication of treatment of ascites
You may not be if
Prisoners
Pregnant women
Subjects undergoing TIPS placement as part of an investigational study outside of usual clinical care
Subjects taking beta-blocker medications or angiotensin converting enzyme inhibitors
Subjects with evidence of porto-systemic shunts present on imaging (eg splenorenal shunt)
Subjects with calculated MELD score \>12 based on most recent laboratory values before consent
Subjects with prior history of overt hepatic encephalopathy (grade 3-4) that was primary reason for hospitalization. Episodes of hepatic encephalopathy that were the consequence of other precipitating event (such as variceal bleeding or infection) will not be considered exclusionary.
Subjects with a known sensitivity to albumin preparations, any ingredient in the formulation, or components of the container
Subjects unable to fast for \>5 hours prior to the HepQuant administration or subjects who are unable to drink the oral dose of the cholate (\~40mL of liquid).
Clareo Health | HepQuant to Predict Hepatic Encephalopathy After TIPS
